Article Versions Notes

Clancy K, Hamill CS, O’Neill WQ, Vu B, Thuener J, Gui S, Li S, Fowler N, Rezaee R, Lavertu P, et al. Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers. 2021; 13(19):4861. https://doi.org/10.3390/cancers13194861

Clancy, Kate, Chelsea S. Hamill, W. Quinn O’Neill, Brandon Vu, Jason Thuener, Shanying Gui, Shawn Li, Nicole Fowler, Rod Rezaee, Pierre Lavertu, and et al. 2021. "Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients" Cancers 13, no. 19: 4861. https://doi.org/10.3390/cancers13194861

Clancy, K., Hamill, C. S., O’Neill, W. Q., Vu, B., Thuener, J., Gui, S., Li, S., Fowler, N., Rezaee, R., Lavertu, P., Wasman, J., Patel, M., Shaikh, H., Vick, E., Madabhushi, A., Wise-Draper, T. M., Burkitt, K., Teknos, T. N., & Pan, Q. (2021). Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers, 13(19), 4861. https://doi.org/10.3390/cancers13194861